Global PD-1 and PD-L1 Inhibitors Market 2022-2026

Description

List of Tables

Technavio has been monitoring the PD-1 and PD-L1 inhibitors market and it is poised to grow by $ 49.34 bn during 2022-2026, accelerating at a CAGR of 19.31% during the forecast period. Our report on the PD-1 and PD-L1 inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of cancer, the presence of patient assistance programs, and the high target affinity and specificity of pd1 and pdl1 inhibitors.

The PD-1 and PD-L1 inhibitors market analysis includes application segment and geographic landscape.

Technavio's PD-1 and PD-L1 inhibitors market is segmented as below:

By Application

Solid tumors
Blood-related tumors

By Geography

North America
Europe
Asia
Rest of World (ROW)

This study identifies the strong pipeline as one of the prime reasons driving the PD-1 and PD-L1 inhibitors market growth during the next few years. Also, strategic alliances and expansion for research areas in pd1 and pdl1 inhibitors will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the PD-1 and PD-L1 inhibitors market covers the following areas:

PD-1 and PD-L1 inhibitors market sizing
PD-1 and PD-L1 inhibitors market forecast
PD-1 and PD-L1 inhibitors market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading PD-1 and PD-L1 inhibitors market vendors that include Akeso Inc., Alphamab Oncology, Amgen Inc., AstraZeneca Plc, BeiGene Ltd., Bristol Myers Squibb Co., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, and Shanghai Jhunsi Biosciences Ltd. Also, the PD-1 and PD-L1 inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR74085

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market by Geography
Exhibit 05: Executive Summary - Chart on Market Segmentation by Application
Exhibit 06: Executive Summary - Chart on Incremental Growth
Exhibit 07: Executive Summary - Data Table on Incremental Growth
Exhibit 08: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 09: Parent market
Exhibit 10: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 11: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 12: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

4.1 Five forces summary
Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
4.2 Bargaining power of buyers
Exhibit 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
4.3 Bargaining power of suppliers
Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
4.4 Threat of new entrants
Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
4.5 Threat of substitutes
Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
4.6 Threat of rivalry
Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
4.7 Market condition
Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Application

5.1 Market segments
Exhibit 24: Chart on Application - Market share 2021-2026 (%)
Exhibit 25: Data Table on Application - Market share 2021-2026 (%)
5.2 Comparison by Application
Exhibit 26: Chart on Comparison by Application
Exhibit 27: Data Table on Comparison by Application
5.3 Solid tumors - Market size and forecast 2021-2026
Exhibit 28: Chart on Solid tumors - Market size and forecast 2021-2026 ($ million)
Exhibit 29: Data Table on Solid tumors - Market size and forecast 2021-2026 ($ million)
Exhibit 30: Chart on Solid tumors - Year-over-year growth 2021-2026 (%)
Exhibit 31: Data Table on Solid tumors - Year-over-year growth 2021-2026 (%)
5.4 Blood-related tumors - Market size and forecast 2021-2026
Exhibit 32: Chart on Blood-related tumors - Market size and forecast 2021-2026 ($ million)
Exhibit 33: Data Table on Blood-related tumors - Market size and forecast 2021-2026 ($ million)
Exhibit 34: Chart on Blood-related tumors - Year-over-year growth 2021-2026 (%)
Exhibit 35: Data Table on Blood-related tumors - Year-over-year growth 2021-2026 (%)
5.5 Market opportunity by Application
Exhibit 36: Market opportunity by Application ($ million)

6 Customer Landscape

6.1 Customer landscape overview
Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

7.1 Geographic segmentation
Exhibit 38: Chart on Market share by geography 2021-2026 (%)
Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
7.2 Geographic comparison
Exhibit 40: Chart on Geographic comparison
Exhibit 41: Data Table on Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
7.4 Europe - Market size and forecast 2021-2026
Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
7.5 Asia - Market size and forecast 2021-2026
Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
7.6 Rest of World (ROW) - Market size and forecast 2021-2026
Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
7.7 US - Market size and forecast 2021-2026
Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
7.8 Germany - Market size and forecast 2021-2026
Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
7.9 Canada - Market size and forecast 2021-2026
Exhibit 66: Chart on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 67: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 68: Chart on Canada - Year-over-year growth 2021-2026 (%)
Exhibit 69: Data Table on Canada - Year-over-year growth 2021-2026 (%)
7.10 UK - Market size and forecast 2021-2026
Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)
7.11 France - Market size and forecast 2021-2026
Exhibit 74: Chart on France - Market size and forecast 2021-2026 ($ million)
Exhibit 75: Data Table on France - Market size and forecast 2021-2026 ($ million)
Exhibit 76: Chart on France - Year-over-year growth 2021-2026 (%)
Exhibit 77: Data Table on France - Year-over-year growth 2021-2026 (%)
7.12 Market opportunity by geography
Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
Exhibit 79: Impact of drivers and challenges in 2021 and 2026
8.4 Market trends

9 Vendor Landscape

9.1 Overview
9.2 Vendor landscape
Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
9.3 Landscape disruption
Exhibit 81: Overview on factors of disruption
9.4 Industry risks
Exhibit 82: Impact of key risks on business

10 Vendor Analysis

10.1 Vendors covered
Exhibit 83: Vendors covered
10.2 Market positioning of vendors
Exhibit 84: Matrix on vendor position and classification
10.3 Amgen Inc.
Exhibit 85: Amgen Inc. - Overview
Exhibit 86: Amgen Inc. - Product / Service
Exhibit 87: Amgen Inc. - Key offerings
10.4 AstraZeneca Plc
Exhibit 88: AstraZeneca Plc - Overview
Exhibit 89: AstraZeneca Plc - Product / Service
Exhibit 90: AstraZeneca Plc - Key news
Exhibit 91: AstraZeneca Plc - Key offerings
10.5 BeiGene Ltd.
Exhibit 92: BeiGene Ltd. - Overview
Exhibit 93: BeiGene Ltd. - Business segments
Exhibit 94: BeiGene Ltd. - Key offerings
Exhibit 95: BeiGene Ltd. - Segment focus
10.6 Bristol Myers Squibb Co.
Exhibit 96: Bristol Myers Squibb Co. - Overview
Exhibit 97: Bristol Myers Squibb Co. - Product / Service
Exhibit 98: Bristol Myers Squibb Co. - Key offerings
10.7 Eli Lilly and Co.
Exhibit 99: Eli Lilly and Co. - Overview
Exhibit 100: Eli Lilly and Co. - Product / Service
Exhibit 101: Eli Lilly and Co. - Key offerings
10.8 F. Hoffmann La Roche Ltd.
Exhibit 102: F. Hoffmann La Roche Ltd. - Overview
Exhibit 103: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 104: F. Hoffmann La Roche Ltd. - Key news
Exhibit 105: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 106: F. Hoffmann La Roche Ltd. - Segment focus
10.9 GlaxoSmithKline Plc
Exhibit 107: GlaxoSmithKline Plc - Overview
Exhibit 108: GlaxoSmithKline Plc - Business segments
Exhibit 109: GlaxoSmithKline Plc - Key news
Exhibit 110: GlaxoSmithKline Plc - Key offerings
Exhibit 111: GlaxoSmithKline Plc - Segment focus
10.10 Merck and Co. Inc.
Exhibit 112: Merck and Co. Inc. - Overview
Exhibit 113: Merck and Co. Inc. - Business segments
Exhibit 114: Merck and Co. Inc. - Key news
Exhibit 115: Merck and Co. Inc. - Key offerings
Exhibit 116: Merck and Co. Inc. - Segment focus
10.11 Merck KGaA
Exhibit 117: Merck KGaA - Overview
Exhibit 118: Merck KGaA - Business segments
Exhibit 119: Merck KGaA - Key news
Exhibit 120: Merck KGaA - Key offerings
Exhibit 121: Merck KGaA - Segment focus
10.12 Sanofi
Exhibit 122: Sanofi - Overview
Exhibit 123: Sanofi - Business segments
Exhibit 124: Sanofi - Key news
Exhibit 125: Sanofi - Key offerings
Exhibit 126: Sanofi - Segment focus

11 Appendix

11.1 Scope of the report
11.2 Inclusions and exclusions checklist
Exhibit 127: Inclusions checklist
Exhibit 128: Exclusions checklist
11.3 Currency conversion rates for US$
Exhibit 129: Currency conversion rates for US$
11.4 Research methodology
Exhibit 130: Research methodology
Exhibit 131: Validation techniques employed for market sizing
Exhibit 132: Information sources
11.5 List of abbreviations
Exhibit 133: List of abbreviations